Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sensei Biotherapeutics, Inc.

0.3442
-0.0168-4.65%
Post-market: 0.34460.0004+0.12%18:43 EDT
Volume:89.18K
Turnover:31.29K
Market Cap:8.68M
PE:-0.30
High:0.3709
Open:0.3700
Low:0.3440
Close:0.3610
Loading ...

Sensei Biotherapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
02 Jun

Sensei Biotherapeutics assumed with a Buy at H.C. Wainwright

TIPRANKS
·
02 Jun

Sensei Biotherapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
23 May

Sensei Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Sensei Biotherapeutics Q1 EPS $(0.27) Misses $(0.22) Estimate

Benzinga
·
06 May

Sensei Biotherapeutics Q1 Operating Expenses USD 7.274 Million

THOMSON REUTERS
·
06 May

Sensei Biotherapeutics Q1 Net Income USD -6.864 Million

THOMSON REUTERS
·
06 May

Press Release: Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Dow Jones
·
06 May

Sensei Biotherapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
05 May

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

GlobeNewswire
·
02 Apr

Sensei Biotherapeutics (SNSE) Gets a Buy from Oppenheimer

TIPRANKS
·
30 Mar

Sensei Biotherapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
28 Mar

Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating

MT Newswires Live
·
28 Mar

Sensei Biotherapeutics Inc : >: Oppenheimer Raises Target Price to $4 From $3.5

THOMSON REUTERS
·
28 Mar

BRIEF-Sensei Biotherapeutics Inc Cash Runway Into Q2 Of 2026

Reuters
·
28 Mar

Sensei Biotherapeutics Inc -Cash Runway Into Q2 of 2026

THOMSON REUTERS
·
28 Mar

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

GlobeNewswire
·
28 Mar

Sensei Biotherapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Buy Rating for Sensei Biotherapeutics Driven by Promising Solnerstotug Trial Results and Strong Financial Projections

TIPRANKS
·
28 Mar

Sensei Biotherapeutics Reports Promising Phase 1/2 Trial Results

TIPRANKS
·
28 Mar